Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.33 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.33 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL831053 | 0.93 | CYP2C8 (0.41) | CYP2C8PTGDR2KMT2ABRD4BRD2 | |
| SCHEMBL832360 | 0.92 | CYP2C8 (0.43) | CYP2C8PTGDR2KMT2AHDAC1HDAC6 | |
| SCHEMBL832052 | 0.91 | CYP2C8 (0.42) | CYP2C8PTGDR2KMT2AMEN1 | |
| SCHEMBL861967 | 0.91 | CYP2C8 (0.44) | CYP2C8PTGDR2KMT2AMEN1 | |
| SCHEMBL831814 | 0.91 | CYP2C8 (0.40) | CYP2C8PTGDR2KMT2ABRD4HDAC1 | |
| SCHEMBL831452 | 0.89 | CYP2C8 (0.40) | CYP2C8PTGDR2KMT2AAKR1B1 | |
| SCHEMBL831258 | 0.88 | CYP2C8 (0.53) | CYP2C8PTGDR2KMT2ABRD4MEN1 | |
| SCHEMBL832068 | 0.86 | CYP2C8 (0.41) | CYP2C8PTGDR2KMT2AAKR1B10AKR1B1 | |
| SCHEMBL12665358 | 0.86 | CYP2C8 (0.51) | CYP2C8PTGDR2KMT2AAKR1B10AKR1B1 | |
| SCHEMBL10256531 | 0.85 | FLT1 (0.41) | CYP2C8PTGDR2KMT2AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | CYP2C8 847/4885PTGDR2 1609/4885KMT2A 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.